166 related articles for article (PubMed ID: 35447281)
1. Up-regulation of NMRK2 mediated by TFE3 fusions is the key for energy metabolism adaption of Xp11.2 translocation renal cell carcinoma.
Chen Y; Yang L; Lu Y; Liu N; Ma W; Fan H; Hu Q; Han X; Gan W; Li D
Cancer Lett; 2022 Jul; 538():215689. PubMed ID: 35447281
[TBL] [Abstract][Full Text] [Related]
2. NONO-TFE3 Fusion Promotes Aerobic Glycolysis and Angiogenesis by Targeting HIF1A in NONO-TFE3 Translocation Renal Cell Carcinoma.
Chen Y; Yang L; Liu N; Shi Q; Yin X; Han X; Gan W; Li D
Curr Cancer Drug Targets; 2021; 21(8):713-723. PubMed ID: 33845743
[TBL] [Abstract][Full Text] [Related]
3. Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma.
Liu N; Chen Y; Yang L; Shi Q; Lu Y; Ma W; Han X; Guo H; Li D; Gan W
Clin Transl Med; 2022 Apr; 12(4):e797. PubMed ID: 35452181
[TBL] [Abstract][Full Text] [Related]
4. The positive regulation loop between NRF1 and NONO-TFE3 fusion promotes phase separation and aggregation of NONO-TFE3 in NONO-TFE3 tRCC.
Wang B; Gan W; Han X; Liu N; Ma T; Li D
Int J Biol Macromol; 2021 Apr; 176():437-447. PubMed ID: 33592266
[TBL] [Abstract][Full Text] [Related]
5. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N
Yang L; Chen Y; Liu N; Shi Q; Han X; Gan W; Li D
J Hematol Oncol; 2021 Mar; 14(1):46. PubMed ID: 33741027
[TBL] [Abstract][Full Text] [Related]
6. LncRNA like NMRK2 mRNA functions as a key molecular scaffold to enhance mitochondrial respiration of NONO-TFE3 rearranged renal cell carcinoma in an NAD
Chen Y; Lu Y; Yang L; Ma W; Dong Y; Zhou S; Liu N; Gan W; Li D
J Exp Clin Cancer Res; 2023 Sep; 42(1):252. PubMed ID: 37770905
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.
Kurahashi R; Kadomatsu T; Baba M; Hara C; Itoh H; Miyata K; Endo M; Morinaga J; Terada K; Araki K; Eto M; Schmidt LS; Kamba T; Linehan WM; Oike Y
Cancer Sci; 2019 Jun; 110(6):1897-1908. PubMed ID: 31006167
[TBL] [Abstract][Full Text] [Related]
8. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
[TBL] [Abstract][Full Text] [Related]
9. TFE3 fusions escape from controlling of mTOR signaling pathway and accumulate in the nucleus promoting genes expression in Xp11.2 translocation renal cell carcinomas.
Yin X; Wang B; Gan W; Zhuang W; Xiang Z; Han X; Li D
J Exp Clin Cancer Res; 2019 Mar; 38(1):119. PubMed ID: 30849994
[TBL] [Abstract][Full Text] [Related]
10. PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renal cell carcinoma.
Wang B; Yin X; Gan W; Pan F; Li S; Xiang Z; Han X; Li D
Autophagy; 2021 Sep; 17(9):2475-2493. PubMed ID: 33019842
[TBL] [Abstract][Full Text] [Related]
11. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
12. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
[TBL] [Abstract][Full Text] [Related]
13. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.
Pflueger D; Sboner A; Storz M; Roth J; Compérat E; Bruder E; Rubin MA; Schraml P; Moch H
Neoplasia; 2013 Nov; 15(11):1231-40. PubMed ID: 24339735
[TBL] [Abstract][Full Text] [Related]
14. Establishment of an ASPL-TFE3 renal cell carcinoma cell line (S-TFE).
Hirobe M; Masumori N; Tanaka T; Kitamura H; Tsukamoto T
Cancer Biol Ther; 2013 Jun; 14(6):502-10. PubMed ID: 23760492
[TBL] [Abstract][Full Text] [Related]
15. Dual role of G-quadruplex in translocation renal cell carcinoma: Exploring plausible Cancer therapeutic innovation.
Neha ; Das P; Verma SP
Biochim Biophys Acta Gen Subj; 2020 Dec; 1864(12):129719. PubMed ID: 32882363
[TBL] [Abstract][Full Text] [Related]
16. Preoperative neutrophil-to-lymphocyte ratio predicts the surgical outcome of Xp11.2 translocation/TFE3 renal cell carcinoma patients.
Agizamhan S; Qu F; Liu N; Sun J; Xu W; Zhang L; Guo H; Gan W
BMC Urol; 2018 Jun; 18(1):60. PubMed ID: 29890986
[TBL] [Abstract][Full Text] [Related]
17. TFE3-Splicing Factor Fusions Represent Functional Drivers and Druggable Targets in Translocation Renal Cell Carcinoma.
Damayanti NP; Cordova RA; Rupert C; Delle Fontane I; Shen L; Orsi S; Klunk AJ; Linehan WM; Staschke KA; Hollenhorst PC; Heppner DE; Pili R
Cancer Res; 2024 Apr; 84(8):1286-1302. PubMed ID: 38266162
[TBL] [Abstract][Full Text] [Related]
18. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
[TBL] [Abstract][Full Text] [Related]
19. CircMET promotes tumor proliferation by enhancing CDKN2A mRNA decay and upregulating SMAD3.
Yang L; Chen Y; Liu N; Lu Y; Ma W; Yang Z; Gan W; Li D
Mol Cancer; 2022 Jan; 21(1):23. PubMed ID: 35042525
[TBL] [Abstract][Full Text] [Related]
20. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
